Oncology News & Articles

1 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, May 23, 2013    Clinical Article

2 Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma Full Text European Urology, May 23, 2013    Clinical Article

3 Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy International Journal of Urology, May 23, 2013    Clinical Article

4 Novel Immunotherapeutic Strategies in Development for Renal Cell Carcinoma Full Text European Urology, May 23, 2013    Review Article

5 To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma World Journal of Urology, May 23, 2013    Clinical Article

6 The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies World Journal of Urology, May 23, 2013    Review Article    Clinical Article

7 Targeted therapies and the treatment of non-clear cell renal cell carcinoma Annals of Oncology, May 23, 2013    Clinical Article

8 Expression profiling of metastatic renal cell carcinoma using gene set enrichment analysis International Journal of Urology, May 23, 2013    Clinical Article

9 A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer Cancer Immunology, Immunotherapy, May 23, 2013    Clinical Article

10 Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data Full Text BMC Cancer, May 23, 2013    Clinical Article

11 NF-kB Inhibition by Bortezomib Permits Interferon-γ-Activated RIP1 Kinase-Dependent Necrosis in Renal Cell Carcinoma. Molecular Cancer Therapeutics, May 23, 2013    Clinical Article

12 Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma Urologic Oncology: Seminars and Original Investigations, May 6, 2013    Clinical Article

13 An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis BJU International, May 6, 2013    Clinical Article

14 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial The Lancet Oncology, May 6, 2013    Clinical Article

15 A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer Annals of Oncology, May 6, 2013    Clinical Article

16 Feasibility and oncological outcomes of laparoscopic treatment for local relapse of renal cell carcinoma BJU International, May 6, 2013    Clinical Article

17 Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort European Journal of Cancer, May 6, 2013    Clinical Article

18 Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib Cancer Chemotherapy and Pharmacology, May 6, 2013    Clinical Article

19 Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients European Journal of Cancer, May 6, 2013    Clinical Article

20 Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer Clinical and Translational Oncology, May 6, 2013    Clinical Article

21 Differential Diagnosis of Renal Tumors With Clear Cytoplasm: Clinical Relevance of Renal Tumor Subclassification in the Era of Targeted Therapies and Personalized Medicine Full Text Archives of Pathology & Laboratory Medicine, May 6, 2013

22 Uric Acid Levels Correlate with Baseline Renal Function and High Levels are a Potent Risk Factor for Postoperative Chronic Kidney Disease in Patients with Renal Cell Carcinoma The Journal of Urology, April 19, 2013    Clinical Article

23 Diagnostic radiation exposure during surveillance in patients with pT1a renal cell carcinoma Urology, April 19, 2013    Clinical Article

24 Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer Journal of the National Cancer Institute, April 19, 2013

25 Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas Clinical Cancer Research, April 19, 2013    Clinical Article

26 Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial British Journal of Cancer, April 19, 2013    Clinical Article

27 STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma Full Text European Urology, April 19, 2013    Clinical Article

28 Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy Medical Oncology, April 19, 2013    Clinical Article

29 Incidence and prognostic significance of second primary cancers in renal cell carcinoma American Journal of Clinical Oncology, April 19, 2013    Clinical Article

30 Skin Cancer Associated With the Use of Sorafenib and Sunitinib for Renal Cell Carcinoma Dermatologic Surgery, April 2, 2013    Clinical Article

31 Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort European Journal of Cancer, April 2, 2013    Clinical Article

32 Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients European Journal of Cancer, April 2, 2013    Clinical Article

33 Association of Thyroid, Breast and Renal Cell Cancer: A Population-based Study of the Prevalence of Second Malignancies Annals of Surgical Oncology, April 2, 2013    Clinical Article

34 Renal Carcinoma After Childhood Cancer: A Report From the Childhood Cancer Survivor Study Journal of the National Cancer Institute, April 2, 2013    Clinical Article

35 Intake of fiber and fiber-rich plant foods is associated with a lower risk of renal cell carcinoma in a large US cohort American Journal of Clinical Nutrition, April 2, 2013    Clinical Article

36 Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008) British Journal of Cancer, April 2, 2013    Clinical Article

37 miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis British Journal of Cancer, April 2, 2013    Clinical Article

38 Renal cell carcinoma with areas mimicking renal angiomyoadenomatous tumor/clear cell papillary renal cell carcinoma Human Pathology, April 2, 2013    Clinical Article

39 Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma Chemotherapy, April 2, 2013    Clinical Article

40 Percutaneous radiofrequency ablation of small renal tumours in patients with a single functioning kidney: long-term results European Radiology, March 16, 2013    Clinical Article

41 Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma Full Text Biologics: targets & therapy, March 16, 2013    Clinical Article

42 Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients British Journal of Cancer, March 16, 2013    Clinical Article

43 Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma British Journal of Cancer, March 16, 2013    Clinical Article

1 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013

2 R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi Journal of Clinical Oncology, April 1, 2013

3 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 2, 2013    Clinical Guideline

4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013

5 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma Neuro-Oncology, April 9, 2013

6 Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study Journal of the National Cancer Institute, April 4, 2013

7 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments BMC Cancer, April 3, 2013    Free full text

8 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial Journal of Clinical Oncology, February 11, 2013

9 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial The Lancet Oncology, March 12, 2013

10 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Annals of Oncology, April 1, 2013

11 High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma European Journal of Cancer, April 5, 2013

12 Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial The Lancet Oncology, April 12, 2013

13 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013

14 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 11, 2013

15 Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer Cancer, April 10, 2013

16 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial The Lancet Oncology, February 15, 2013

17 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab: Results of the randomised GeparQuinto study (GBG 44) European Journal of Cancer, April 5, 2013

18 Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology, April 4, 2013

19 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013

20 R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma British Journal of Haematology, March 1, 2013